This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate effective statin doses.
Background
Statin intolerance, which is predominantly due to muscle-related side effects, is reported in up to 10% to 20% of patients. Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrated marked reductions in plasma low-density lipoprotein cholesterol (LDL-C) in a phase 2 study in statinintolerant patients.
Methods
The GAUSS-2 (Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects) trial was a 12-week, double-blind study of randomized patients (2:2:1:1) to evolocumab 140 mg every two weeks (Q2W) or evolocumab 420 mg once monthly (QM) both with daily oral placebo or subcutaneous placebo Q2W or QM both with daily oral ezetimibe 10 mg. Co-primary endpoints were percent change from baseline in LDL-C at the mean of weeks 10 and 12, and at week 12.
Results
Three hundred seven patients (age 62 AE 10 years; LDL-C 193 AE 59 mg/dl) were randomized. Evolocumab reduced LDL-C from baseline by 53% to 56%, corresponding to treatment differences versus ezetimibe of 37% to 39% (p <0.001). Muscle adverse events occurred in 12% of evolocumab-treated patients and 23% of ezetimibe-treated patients. Treatment-emergent adverse events and laboratory abnormalities were comparable across treatment groups.
Conclusions
Robust efficacy combined with favorable tolerability makes evolocumab a promising therapy for addressing the largely unmet clinical need in high-risk patients with elevated cholesterol who are statin intolerant. Lowering low-density lipoprotein cholesterol (LDL-C) with statins reduces cardiovascular risk (1, 2) . Although statins are well tolerated, statin-related adverse events have been reported more commonly than in the randomized trials, reaching up to 10% to 20% of patients (3). Although Zhang et al. (3) reported that a substantial proportion of patients with side effects to 1 statin tolerated a rechallenge to a second statin, failure to achieve treatment target in patients intolerant of multiple statins is expected to translate into lower benefits in cardiovascular risk (1) (2) (3) (4) . The cholesterol absorption inhibitor, ezetimibe, is well tolerated, but yields only a minor reduction in LDL-C. Other therapies include bile acid sequestrants and nicotinic acid, but these agents are usually poorly tolerated. Novel potent LDL-C lowering therapies, such as the apolipoprotein-B synthesis inhibitor and the microsomal triglyceride transfer protein inhibitor, are characterized by marked side effects, limiting wider usage (5, 6) .
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein involved in regulating low-density lipoprotein receptor (LDLR) recycling (7) (8) (9) . Evolocumab (AMG 145) is a fully human monoclonal antibody that binds to PCSK9 and inhibits its interaction with the LDLR, resulting in increased receptor recycling and LDL clearance. In a phase 2 dose-finding study, evolocumab reduced LDL-C in statin-intolerant patients and showed favorable short-term tolerability (10) . We now report on the GAUSS-2 (Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2) trial (11), a phase 3 study that compared the effects of evolocumab with ezetimibe in statin-intolerant hypercholesterolemic patients. Compared with GAUSS, which included patients intolerant to at least 1 statin, the present phase 3 trial evaluated evolocumab compared with ezetimibe using a placebo-controlled design in patients intolerant to at least 2 statins.
Methods
Patients. GAUSS-2 enrolled patients aged 18 to 80 years on no or low-dose statins. Participants had LDL-C above their National Cholesterol Education Program (NCEP) Adult Treatment Panel III goal (12) . Participants had previous intolerance to !2 statins, defined as inability to tolerate any dose or increase the dose above the smallest tablet strength because of intolerable muscle-related side effects (11) .
Study design and oversight. The institutional review boards approved the protocol, and all patients provided written informed consent. GAUSS-2 was a randomized, double-blind, phase 3, placebo-and ezetimibe-controlled study (11) . Patients were randomized 2:2:1:1 to subcutaneous evolocumab 140 mg every two weeks (Q2W) or evolocumab 420 mg once monthly (QM) both with daily oral placebo or subcutaneous placebo Q2W or QM both with daily oral ezetimibe. Patients and all study personnel were blinded to treatment assignment. An independent data monitoring committee reviewed all data. Study procedures. Study procedures were similar to those listed in the MENDEL-2 (Anti-PCKS9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab) study (13) . Efficacy and safety evaluations. Co-primary endpoints were percent change from baseline in LDL-C at the mean of weeks 10 and 12 and at week 12. Co-secondary efficacy endpoints at the same time points included change from baseline in LDL-C, percent of patients with LDL-C <70 mg/dl, and percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein B, total cholesterol/HDL-C ratio, apolipoprotein B/apolipoprotein A-I ratio, lipoprotein(a), triglycerides, HDL-C, and very low-density lipoprotein (VLDL-C) (10) . Safety endpoints included treatment-emergent and serious adverse events, creatine kinase (CK) and hepatic enzyme elevations, and anti-evolocumab antibodies. Statistical analysis. Planned enrollment of 300 patients (200 on evolocumab) had !92% power to detect superiority of evolocumab regimens over ezetimibe based on a 2-sided ttest with 0.05 significance level for co-primary endpoints. Statistical analyses were similar to those in the MENDEL-2 study (13) .
Results
Patients. Between January and August 2013, 307 patients were randomized to evolocumab (n ¼ 205) or ezetimibe (n ¼ 102) ( Table 1, Online Table S1 ). Patients had a baseline LDL-C of 193 AE 59 mg/dl. Lipid-lowering therapy was used by 33% of patients; 18% received a low-dose statin. Fifty-six percent of patients were at high risk of coronary heart disease (CHD) according to the NCEP. Treatment was completed by 96% of patients on evolocumab and 86% of patients on ezetimibe. Eight patients discontinued evolocumab (4%) for adverse events (n ¼ 6), patient request (n ¼ 1), or loss to follow-up (n ¼ 1). Fourteen patients discontinued ezetimibe (14%) for adverse events (n ¼ 11), patient request (n ¼ 2), or other reason (n ¼ 1). The study was completed by 290 patients (94%) (Online Fig. S1 ). Efficacy outcomes. LOW-DENSITY LIPOPROTEIN CHOLESTEROL. Evolocumab yielded significant reductions in LDL-C ( Table 2) . Mean percent reductions from baseline at a mean of weeks 10 and 12 were 56.1% (95% confidence interval [CI]: 59.7% to 52.5%) with 140 mg Q2W and 55.3% (95% CI: 58.3% to 52.3%) with 420 mg QM, corresponding to treatment differences versus ezetimibe of 36.9% (95% CI: 42.3% to 31.6%) and 38.7% (95% CI: 43.1% to 34.3%), respectively (p <0.001). Mean percent reductions from baseline and treatment differences at week 12 were similar (p < 0.001). Reductions in LDL-C were sustained throughout the trial (Fig  1) . Evolocumab-treated patients were more likely to achieve LDL-C target levels than ezetimibe-treated patients (Fig. 2) .
OTHER LIPIDS. Compared with ezetimibe, evolocumab led to significant reductions in apolipoprotein B, lipoprotein(a), non-HDL-C, and the apolipoprotein B/apolipoprotein A-I and total cholesterol/HDL-C ratios (p < 0.001) ( Table 2,  Online Table S2 ). Safety outcomes. Treatment-emergent adverse events are listed in Table 3 and the Online Appendix. Adverse events led to study drug discontinuation in 8% (evolocumab) and 13% (ezetimibe) of patients. Myalgia occurred in 8% of Values are mean AE SD or n (%), unless otherwise noted. *Data are missing for 1 patient in the evolocumab Q2W arm; myalgia, muscle symptoms without creatine kinase (CK) elevation; myositis, muscle symptoms with CK elevation; rhabdomyolysis, muscle symptoms with marked CK elevation. yCHD in male first-degree relative at <55 years of age or in female first-degree relative at <65 years of age. zDefined as <40 mg/dl in men and <50 mg/dl in women. xRisk category definitions: high (diagnosed CHD or risk equivalent); moderately high (2 or more risk factors and Framingham risk score 10% to 20%); moderate (2 or more risk factors and Framingham risk score <10%); and lower (0 or 1 risk factor). CHD ¼ coronary heart disease; CV ¼ cardiovascular; HDL-C ¼ high-density lipoprotein cholesterol; IQR ¼ interquartile range; LDL-C ¼ low-density lipoprotein cholesterol; NCEP ¼ National Cholesterol Education Program; PBO ¼ placebo; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; Q2W ¼ every 2 weeks; QD ¼ daily; QM, ¼ monthly.
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Evolocumab in Statin-Intolerant Patients evolocumab-treated patients and 18% of ezetimibe-treated patients. Patients using low-dose statin therapy were more likely to develop myalgia in the ezetimibe (statin vs. no statin: 21% vs. 17%) and the evolocumab group (statin vs. no statin: 17% vs 6%). Discontinuation rates due to musculoskeletal side effects were 5% (evolocumab) and 6% (ezetimibe). No binding or neutralizing antibodies to evolocumab were detected.
Discussion
In the GAUSS-2 study, evolocumab administered over 3 months yielded a significant reduction in LDL-C in hypercholesterolemic patients who were unable to tolerate effective doses of at least 2 statins, reflecting a population with a true unmet need. Values are mean AE SD or least squares mean (95% confidence interval) unless otherwise specified. Least squares mean is from the repeated measures model, including covariates of stratification factors, treatment group, scheduled visit, and interaction of treatment with scheduled visits. *Co-primary endpoint. yAdjusted p value versus ezetimibe <0.001; multiplicity adjustments within each dose frequency were used to control for the overall significance level for all primary and secondary endpoints. Abbreviations as in Table 1 .
JACC
Evolocumab treatment resulted in a 53% to 56% reduction in LDL-C, with comparable reductions between dosing regimens. In GAUSS-2, 82% of patients used no statin, leading to markedly elevated LDL-C levels (mean of 193 mg/dl) comparable to those observed in early secondary prevention trials (14) . Of evolocumab-treated patients at high risk, more than 75% achieved LDL-C <100 mg/dl compared with less than 10% of ezetimibe-treated patients. In the context of the American College of Cardiology/ American Heart Association guidelines (15) , these findings imply that evolocumab could be a promising alternative agent to lower LDL-C in statin-intolerant patients with markedly elevated LDL-C levels.
Compared with the dose-finding phase 2 trial (GAUSS) (10), GAUSS-2 enrolled a population at a higher cardiovascular risk, with more patients intolerant of at least 2 statins, leading to the inclusion of patients with a truly unmet clinical need. In the upcoming results of the outcome trial with evolocumab (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk; NCT01764633), the observed 100 mg/dl reduction in LDL-C can be expected to reduce cardiovascular risk, given the 22% risk reduction per 39 mg/dl LDL-C decrease reported for statins (1, 2) .
In GAUSS-2, ezetimibe was selected as comparator based on its favorable tolerability and widespread use in statinintolerant patients (16) . The majority of patients using ezetimibe were unable to achieve LDL-C target levels, as evidenced by the 2% rate of achieving LDL-C <70 mg/dl. Moreover, benefit of ezetimibe-induced, LDL-C lowering awaits confirmation in the ongoing outcome study (IMPROVE-IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]; NCT00202878) (17) .
Evolocumab also reduced lipoprotein(a) levels by 27% (Q2W) and 22% (QM) at week 12, consistent with lipoprotein(a) reductions reported in previous studies using PCSK9-targeting programs (18) (19) (20) . Further studies on the mechanism of lipoprotein(a) lowering and the benefit of evolocumab in patients with elevated lipoprotein(a) levels are warranted. Evolocumab was well tolerated with 96% of patients completing treatment. With all patients having historically experienced muscle-related side effects during statin therapy, myalgia incidence was low (18%, 7%, and 9% of patients in the ezetimibe, evolocumab Q2W, and evolocumab QM groups, respectively). In the MENDEL-2 study (13), these rates were 1%, 1%, and 1%, respectively. Notwithstanding the higher rate in statin-intolerant patients, there was no increase in muscle-related side effects in the evolocumab-compared with ezetimibe-treated patients. This suggests that the pathways contributing to statinassociated myalgia and/or myositis (21, 22) are distinct from those contributing to PCSK9 antibody-mediated LDL-C lowering. Because the study was short term, these data await confirmation in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; NCT01764633) outcome study. The incidence of treatment-emergent adverse events and laboratory abnormalities were comparable across treatment groups. Study limitations. A limitation of this study includes the absence of a blinded statin re-challenge. We used a real-life definition of patients who experienced intolerable muscle-related side effects to !2 statins, with the majority unable to tolerate !3 statins. A placebo-controlled blinded statin re-challenge has, however, been included in the GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3; NCT01984424) study. Another limitation is the short study duration in patients needing life-long treatment; 
Conclusions
Evolocumab treatment yielded a robust reduction in plasma LDL-C in hypercholesterolemic patients with statin intolerance. The low incidence of muscle-related side effects in GAUSS-2 underscores evolocumab as a useful therapy for hypercholesterolemic patients who presently have few tolerable treatment options, provided that benefit is confirmed in the ongoing endpoint trial (FOURIER; NCT01764633).
